• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    27 Stocks Moving in Monday's Pre-Market Session

    3/1/22 5:47:58 AM ET
    $AREB
    $ATXI
    $AVGR
    $AVIR
    Plastic Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AREB alert in real time by email

    Gainers

    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) rose 28.6% to $1.71 in pre-market trading. American Rebel recently reported closing of $10.5 million public offering.
    • VEON Ltd. (NASDAQ:VEON) rose 27.5% to $0.6570 in pre-market trading. VEON reported its intention to share access to its Augmented Intelligence Platform capabilities and know-how with the international mobile operator community.
    • GBS Inc. (NASDAQ:GBS) rose 26.1% to $0.58 in pre-market trading after declining around 9% on Monday.
    • NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) rose 19.2% to $3.10 in pre-market trading after jumping 68% on Monday.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 17.2% to $1.98 in pre-market trading after gaining over 145% on Monday. Mullen Automotive recently announced progress on solid-state polymer battery pack development.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) shares rose 15.3% to $0.6809 in pre-market trading.
    • Ucommune International Ltd (NASDAQ:UK) shares rose 12% to $0.4550 in pre-market trading after dipping around 17% on Monday.
    • Supernova Partners Acquisition Company II, Ltd. (NYSE:SNII) rose 11.5% to $11.05 in pre-market trading after gaining over 6% on Monday.
    • 3D Systems Corporation (NYSE:DDD) rose 11.2% to $19.84 in pre-market trading after the company reported better-than-expected Q4 results.
    • Avinger, Inc. (NASDAQ:AVGR) rose 11.1% to $0.2888 in pre-market trading. Avinger recently reported successful completion of first cases with Lightbox 3 next generation imaging console.
    • Editas Medicine, Inc. (NASDAQ:EDIT) rose 11% to $19.00 in pre-market trading as the company reported favorable decision from U.S. Patent and Trademark Office in CRISPR patent interference.
    • NextDecade Corporation (NASDAQ:NEXT) rose 10.3% to $3.74 in pre-market trading after surging 21% on Monday.
    • Secoo Holding Limited (NASDAQ:SECO) rose 8.9% to $0.4353 in pre-market trading after climbing around 22% on Monday.
    • Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) rose 8.4% to $6.87 in pre-market trading following upbeat Q4 results.
    • Puhui Wealth Investment Management Co., Ltd. (NASDAQ:PHCF) rose 7% to $1.37 in pre-market trading after climbing over 18% on Monday.


    Losers

    • GoodRx Holdings, Inc. (NASDAQ:GDRX) shares fell 30.9% to $18.94 in pre-market trading after the company reported worse-than-expected Q4 EPS and sales results and issued Q1 sales guidance below estimates.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) fell 14.6% to $0.1862 in pre-market trading after jumping 45% on Monday.
    • Vroom, Inc. (NASDAQ:VRM) fell 13.7% to $5.25 in pre-market trading after reporting a wider-than-expected Q4 loss.
    • Lucid Group, Inc. (NASDAQ:LCID) fell 13.2% to $25.15 in pre-market trading after the company reported worse-than-expected Q4 sales results and cut FY22 production guidance.
    • PubMatic, Inc. (NASDAQ:PUBM) shares fell 11.4% to $27.10 in pre-market trading after the company issued Q1 sales guidance below estimates.
    • DSS, Inc. (NYSE:DSS) shares fell 11% to $0.5035 in pre-market trading after jumping 47% on Monday.
    • Motus GI Holdings, Inc. (NASDAQ:MOTS) shares fell 11% to $0.3137 in pre-market trading. Motus GI recently received FDA clearance to market its Pure-Vu EVS System.
    • Groupon, Inc. (NASDAQ:GRPN) shares fell 10.9% to $19.36 in pre-market trading after the company reported worse-than-expected Q4 EPS and sales results and issued Q1 sales guidance below estimates.
    • Cyren Ltd. (NASDAQ:CYRN) fell 9.1% to $5.32 in pre-market trading.
    • Vital Farms, Inc. (NASDAQ:VITL) fell 7.7% to $13.15 in pre-market trading. Vital Farms is expected to release Q4 results on March 10.
    • Novavax, Inc. (NASDAQ:NVAX) fell 7.6% to $77.00 in pre-market trading after the company reported Q4 EPS and sales results were down year over year.
    Get the next $AREB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREB
    $ATXI
    $AVGR
    $AVIR

    CompanyDatePrice TargetRatingAnalyst
    NextDecade Corporation
    $NEXT
    2/6/2026$7.00Overweight
    CapitalOne
    GoodRx Holdings Inc.
    $GDRX
    1/22/2026$2.75Buy → Hold
    Jefferies
    GoodRx Holdings Inc.
    $GDRX
    12/9/2025$3.00Underweight
    Barclays
    Lucid Group Inc.
    $LCID
    12/8/2025$10.00Equal-Weight → Underweight
    Morgan Stanley
    Vital Farms Inc.
    $VITL
    12/5/2025$45.00Buy
    Needham
    Vital Farms Inc.
    $VITL
    11/13/2025$60.00Buy
    The Benchmark Company
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    NextDecade Corporation
    $NEXT
    10/23/2025$8.00 → $7.00Hold
    TD Cowen
    More analyst ratings

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CapitalOne initiated coverage on NextDecade with a new price target

    CapitalOne initiated coverage of NextDecade with a rating of Overweight and set a new price target of $7.00

    2/6/26 8:35:07 AM ET
    $NEXT
    Oil & Gas Production
    Utilities

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    $AREB
    $ATXI
    $AVGR
    $AVIR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Atea Pharmaceuticals Inc.

    SCHEDULE 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    2/9/26 2:02:27 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NeuroSense Therapeutics Ltd.

    6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

    2/9/26 9:30:05 AM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Novavax Inc.

    SCHEDULE 13G - NOVAVAX INC (0001000694) (Subject)

    2/9/26 7:56:48 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hanwha Aerospace Co., Ltd. bought $9,399,378 worth of shares (1,651,971 units at $5.69) (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    12/15/25 7:12:58 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    Large owner Hanwha Aerospace Co., Ltd. bought $5,742,414 worth of shares (932,598 units at $6.16) (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    12/10/25 8:15:10 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    Large owner Hanwha Aerospace Co., Ltd. bought $3,910,470 worth of shares (636,963 units at $6.14) (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    12/5/25 6:29:01 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/9/26 5:49:36 PM ET
    $GDRX
    EDP Services
    Technology

    EXECUTIVE CHAIRPERSON Ohayer Matthew sold $558,136 worth of shares (20,000 units at $27.91), decreasing direct ownership by 0.31% to 6,341,190 units (SEC Form 4)

    4 - Vital Farms, Inc. (0001579733) (Issuer)

    2/4/26 4:55:03 PM ET
    $VITL
    Packaged Foods
    Consumer Staples

    Director Beall Pamela K.M. was granted 30,245 shares, increasing direct ownership by 447% to 37,007 units (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    2/3/26 9:37:25 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Announces Appointment of Neil Marsons as Senior Vice President of Supply Chain

    NEWARK, Calif., Feb. 9, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced Neil Marsons has joined the organization as the Senior Vice President of Supply Chain. Bringing more than 20 years of experience to the role, Marsons will be responsible for expanding and strengthening the company's global supply chain, as well as closely partnering across the organization to support production at the company's facilities in Arizona and Saudi Arabia. Previously, Marsons served as the Group Chief Procurement Officer

    2/9/26 10:49:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

    Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled "Compositions Comprising Ciprofloxacin and Celecoxib," representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC. The granted Australian patent, following prior approval of the corresponding U.S. patent (12,097,185), further expands 

    2/9/26 9:20:00 AM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guardforce AI Signs Non-binding Letter of Intent to Acquire Leading AI-Powered Speech Therapy and Development Platform

    NEW YORK, NY, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited ("Guardforce AI" or the "Company") (NASDAQ:GFAI, GFAIW)), an AI-driven technology company providing Agentic AI, smart solutions in automation, robotics, and secured logistics, today announced it has entered into a non-binding Letter of Intent (LOI) to acquire 100% of the issued and outstanding share capital of MGAI Limited ("MGAI"), a pioneer in AI-driven solutions for speech therapy and development management and rehabilitation services. Utilizing advanced AI technology and one of China's largest domestic databases for children's language development assessment, MGAI has built a service ecosystem combining proprie

    2/9/26 8:30:00 AM ET
    $GFAI
    Diversified Commercial Services
    Consumer Discretionary

    $AREB
    $ATXI
    $AVGR
    $AVIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Announces Appointment of Neil Marsons as Senior Vice President of Supply Chain

    NEWARK, Calif., Feb. 9, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced Neil Marsons has joined the organization as the Senior Vice President of Supply Chain. Bringing more than 20 years of experience to the role, Marsons will be responsible for expanding and strengthening the company's global supply chain, as well as closely partnering across the organization to support production at the company's facilities in Arizona and Saudi Arabia. Previously, Marsons served as the Group Chief Procurement Officer

    2/9/26 10:49:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    PubMatic Expands Commercial Leadership Team to Accelerate Buy-Side and Publisher Growth

    New executive and senior leadership appointments deepen PubMatic's brand, agency, and publisher partnerships across CTV, mobile app, and omnichannel media PubMatic (NASDAQ:PUBM), the leading AI-powered ad tech company delivering digital advertising performance, today announced a major expansion of its commercial leadership team, signaling the company's next phase of growth as demand accelerates for AI-driven buying across premium connected TV (CTV), mobile app, and omnichannel media. Anchored by the strategic appointments of Joseph Dressler as Senior Vice President, Advertiser Solutions (Brands) and Bill McLaughlin as Senior Vice President, Advertiser Solutions (Agencies), the expanded

    1/27/26 9:00:00 AM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    Lucid Gravity SUV and Lucid Air Sedan Named to Car and Driver's Prestigious 10Best for 2026

    Lucid Air named to Car and Driver's 10Best Cars list for the third straight year; Lucid Gravity named to the 10Best Trucks & SUVs list in its first year of eligibility NEWARK, Calif., Dec. 16, 2025 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced that Car and Driver has selected both Lucid Gravity and Lucid Air to join its esteemed 10Best lists for 2026 following a rigorous evaluation process. Car and Driver's 10Best lists recognize the top 10 vehicles on the road today in two key segments – cars and trucks/SUVs – which stand out to editors with their respective combinations of value, fulfillment of mission, and overall dr

    12/16/25 9:05:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by DSS Inc.

    SC 13D/A - DSS, INC. (0000771999) (Subject)

    12/12/24 9:56:52 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREB
    $ATXI
    $AVGR
    $AVIR
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    PubMatic to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    PubMatic, Inc. (NASDAQ:PUBM), the leading AI-powered ad tech company delivering digital advertising performance, today announced that it will release its financial results for the quarter and fiscal year ended December 31, 2025 after market close on Thursday, February 26, 2026. On that day, PubMatic will host a webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss the company's financial results. Webcast Details What: PubMatic's Fourth Quarter and Full Year 2025 Earnings Webcast When: Thursday, February 26, 2026, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Webcast: A live and archived webcast can be accessed from the News & Events section of PubMatic's In

    1/20/26 8:30:00 AM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    Lucid Announces Q4 Production & Deliveries, Sets Date for Fourth Quarter 2025 Results

    NEWARK, Calif., Jan. 5, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced production and delivery totals for the quarter and year ended December 31, 2025. On a full year basis in 2025, the company produced 18,378 vehicles, up 104% compared to full year 2024, and delivered 15,841 vehicles, up 55% compared to full year 2024. During Q4 2025, Lucid produced 8,412 vehicles, up 116% compared to Q3 2025, and delivered 5,345 vehicles, up 31% compared to Q3 2025.1 Lucid will host a conference call to discuss its

    1/5/26 9:00:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials